Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol

Lipids

Volumn 45, Issue 4, 2010, Pages 321-327

  Nakhjavani, Manouchehr ^a   Khalilzadeh, Omid ^a   Khajeali, Leila ^a   Esteghamati, Alireza ^a   Morteza, Afsaneh ^a   Jamali, Arsia ^a   Dadkhahipour, Sheida ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; Duration; Ox LDL

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PROCESS OPTIMIZATION; REFERENCE VALUE;

ADMINISTRATION, ORAL; ADULT; AGE OF ONSET; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS;

EID: 77953289382     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-010-3401-8     Document Type: Article

References (45)

1. Renie G, Maingrette F, Li L (2007) Diabetic vasculopathy and the lectin-like oxidized low-density lipoprotein receptor-1 (LOX- 1). Curr Diabetes Rev 3:103-110
2. Brownlee M (2005) The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54:1615-1625
3. Wei W, Liu Q, Tan Y, Liu L, Li X, Cai L (2009) Oxidative stress, diabetes, and diabetic complications. Hemoglobin 33:370-377
4. Piarulli F, Lapolla A, Sartore G, Rossetti C, Bax G, Noale M, Minicuci N, Fiore C, Marchioro L, Manzato E, Fedele D (2005) Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. Diabetes Care 28:653-657
5. Rashidi A, Nakhjavani M, Esteghamati A, Asgarani F, Khalilzadeh O, Abbasi M, Safari R (2009) Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: Results in 142 patients. J Nephrol 22(6):733-738
6. Nakhjavani M, Esteghamati A, Khalilzadeh O, Asgarani F, Mansournia N, Abbasi M (2009) Association of macroalbuminuria with oxidized LDL and TGF-beta in type 2 diabetic patients: A case-control study. Int Urol Nephrol [Epub ahead of print]
7. Veiraiah A (2005) Hyperglycemia, lipoprotein glycation, and vascular disease. Angiology 56:431-438
8. Woodman RJ, Watts GF, Playford DA, Best JD, Chan DC (2005) Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes. Diabetes Obes Metab 7:612-617
9. Silverstein RL (2009) Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med 76(Suppl 2):S27-S30
10. Silverstein RL (2001) Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
11. Rosenson RS (2004) Statins in atherosclerosis: Lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173:1-12
12. Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF (1995) Comparison of gemfibrozil versus simvastatin infamilial combined hyperlipidemia and effects on apolipoprotein- B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 75:348-353
13. American Diabetes Association (2008) Diagnosis and classification of diabetes mellitus. Diabetes Care 31(Suppl 1):S55-S60
14. Lapointe A, Couillard C, Piche ME, Weisnagel SJ, Bergeron J, Nadeau A, Lemieux S (2007) Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women. Atherosclerosis 191:362-368
15. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr (2008) Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299:2287-2293
16. Nakhjavani M, Esteghamati A, Asgarani F, Khalilzadeh O, Nikzamir A, Safari R (2009) Association of oxidized low-density lipoprotein and transforming growth factor-beta in type 2 diabetic patients: A cross-sectional study. Transl Res 153:86-90
17. Njajou OT, Kanaya AM, Holvoet P, Connelly S, Strotmeyer ES, Harris TB, Cummings SR, Hsueh WC (2009) Association between oxidized LDL, obesity and type 2 diabetes in a population- based cohort, the Health, Aging and Body Composition Study. Diabetes Metab Res Rev 25:733-739
18. Gokulakrishnan K, Deepa R, Velmurugan K, Ravikumar R, Karkuzhali K, Mohan V (2007) Oxidized low-density lipoprotein and intimal medial thickness in subjects with glucose intolerance: The Chennai Urban Rural Epidemiology Study-25. Metabolism 56:245-250
19. Girona J, Manzanares JM, Marimon F, Cabre A, Heras M, Guardiola M, Ribalta J, Masana L (2008) Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. Nutr Metab Cardiovasc Dis 18:380-387
20. Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y (2008) The oxidation ratio of LDL: A predictor for coronary artery disease. Dis Markers 24:341-349
21. Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, Kumon Y, Hashimoto K (2004) Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 53:297-302 (Pubitemid 38684688)
22. El-Bassiouni EA, Helmy MH, El-Zoghby SM, El-Nabi Kamel MA, Hosny RM (2007) Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients. Br J Biomed Sci 64:109-116
23. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W (2005) Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112:651-657
24. Hulthe J, Fagerberg B (2002) Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22:1162-1167
25. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y (2008) Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118:75-83
26. Steinberg D (1997) Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963-20966
27. Young IS, McEneny J (2001) Lipoprotein oxidation and atherosclerosis. Biochem Soc Trans 29:358-362
28. Rahimi R, Nikfar S, Larijani B, Abdollahi M (2005) A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 59:365-373
29. Scheffer PG, Teerlink T, Heine RJ (2005) Clinical significance of the physicochemical properties of LDL in type 2 diabetes. Diabetologia 48:808-816
30. Matsui J, Onuma T, Tamasawa N, Suda T (1997) Effects of advanced glycation endproducts on the generation of macrophage- mediated oxidized low-density lipoprotein. J Diabetes Complicat 11:338-342
31. Scott JA, King GL (2004) Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci 1031:204-213
32. Lipinski B (2001) Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complicat 15:203-210
33. Chen X, Zhang T, Du G (2008) Advanced glycation end products serve as ligands for lectin-like oxidized low-density lipoprotein receptor-1(LOX-1): Biochemical and binding characterizations assay. Cell Biochem Funct 26:760-770
34. van der Zwan LP, Teerlink T, Dekker JM, Henry RM, Stehouwer CD, Jakobs C, Heine RJ, Scheffer PG (2009) Circulating oxidized LDL: Determinants and association with brachial flow-mediated dilation. J Lipid Res 50:342-349
35. Duarte MM, Rocha JB, Moresco RN, Duarte T, Da Cruz IB, Loro VL, Schetinger MR (2009) Association between ischemiamodified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 42:666-671
36. Holvoet P (2008) Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 70:193-219
37. Lee IT, Chan YC, Lin CW, Lee WJ, Sheu WH (2008) Effect of cranberry extracts on lipid profiles in subjects with type 2 diabetes. Diabet Med 25:1473-1477
38. Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S (2008) Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels 23:249-256
39. Obata T, Yonemoti H, Aomine M (2009) The protective effect of fluvastatin on hydroxyl radical generation by inhibiting lowdensity lipoprotein (LDL) oxidation in the rat myocardium. Microvasc Res 77:163-165
40. Fisher NM, Meksawan K, Limprasertkul A, Isackson PJ, Pendergast DR, Vladutiu GD (2007) Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation. J Inherit Metab Dis 30:388-399
41. van Tits LJ, van Himbergen TM, Lemmers HL, de Graaf J, Stalenhoef AF (2006) Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185:307-312
42. Antonopoulos AS, Antoniades C, Tousoulis D, Bakogiannis C, Demosthenous M, Psarros C, Stefanadis C (2009) Novel therapeutic strategies targeting vascular redox in human atherosclerosis. Recent Pat Cardiovasc Drug Discov 4:76-87
43. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, Labuzek K, Herman ZS (2004) The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176:327-335
44. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F (2000) Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36:427-431
45. Rosenson RS, Tangney CC, Parker TS, Levine DM, Gordon BR (2002) Statin therapy reduces oxidative stress and inhibits monocyte chemoattractant protein-1 (MCP-1) production in healthy adults with moderate hypercholesterolemia. Circulation 106(Suppl II):A3669